The estimated Net Worth of Health, Inc. Opko is at least $2.17 Milhão dollars as of 30 October 2017. Health Opko owns over 655,738 units of VBI Vaccines stock worth over $467,513 and over the last 11 years Health sold VBIV stock worth over $1,698,080.
Health has made over 10 trades of the VBI Vaccines stock since 2013, according to the Form 4 filled with the SEC. Most recently Health bought 655,738 units of VBIV stock worth $2,000,001 on 30 October 2017.
The largest trade Health's ever made was buying 655,738 units of VBI Vaccines stock on 30 October 2017 worth over $2,000,001. On average, Health trades about 84,680 units every 145 days since 2013. As of 30 October 2017 Health still owns at least 6,678,752 units of VBI Vaccines stock.
You can see the complete history of Health Opko stock trades at the bottom of the page.
Health's mailing address filed with the SEC is 4400, Biscayne Boulevard, Buena Vista, Miami, Miami-Dade County, Florida, 33137, United States.
Over the last 8 years, insiders at VBI Vaccines have traded over $18,633,012 worth of VBI Vaccines stock and bought 55,142,222 units worth $66,770,591 . The most active insiders traders include Advisors Llcperceptive Life..., Tomer Kariv, eSteven D Rubin. On average, VBI Vaccines executives and independent directors trade stock every 62 days with the average trade being worth of $130,457. The most recent stock trade was executed by Steven Gillis on 10 July 2023, trading 609,090 units of VBIV stock currently worth $1,004,999.
vbi vaccines inc. (nasdaq: vbiv) is a biopharmaceutical company developing novel technologies that seek to expand vaccine protection in large underserved markets. vbi’s evlp vaccine platform allows for the design of enveloped (“e”) virus-like particle (“vlp”) vaccines that closely mimic the target virus. the company’s lead evlp asset is a prophylactic cytomegalovirus (cmv) vaccine; vbi has initiated work for gmp manufacturing of its cmv candidate for use in formal preclinical and phase i trials. the company’s second platform is a thermostable technology that enables the development of vaccines and biologics that can withstand storage or shipment at constantly fluctuating temperatures. vbi has completed proof of concept thermostability studies on a number of vaccine and biologic targets. vbi is headquartered in cambridge, ma with research facilities in ottawa, canada.
VBI Vaccines executives and other stock owners filed with the SEC include: